Friday, 19 Jan 2018

You are here

Supreme Court Decision Favors Earlier Biosimilar Adoption

On Monday June 11th, the US Supreme Court unanimously ruled that biosimilar manufacturers can bring their drugs to market faster by eliminating the provision that the biosimar manufacturer had to give the innovator company 180 days notice before launching the new biosimilar.

The court was asked to decide on biosimilar patent dispute resolution procedures of the Biologics Price Competition and Innovation Act (BPCIA) or what has been called the "patent dance".  In the first part of the patent dance, the Court ruled against the requirement that a biosimilar applicant share its biosimilar application with the reference product sponsor.

The second ruling regarding a premarketing notice requirement, the Court held that the biosimilar applicant does not have to wait for FDA approval before giving 180-day premarketing notice, as long as there are no existing injunctions stemming from pending patent litigation.

The judgement stems from a dispute in Sandoz v. Amgen over Zarxio (the first biosimilar approved) competing with Amgen's Neulasta (pegfilgastrim or G-CSF).  A lower court had previously ruled against Sandoz challenge to the 180 day wait.  The Supreme Court ruled 9-0 in favor of Sandoz's assertion that a biosimilar manufacturers should not have to wait an extra six months after FDA approval to launch the new biosimilar product.

Sandoz's drug costs about 15 percent less than the brand name and Amgen has had 12 years of market exclusivity with the product. Sandoz argued that the 180 day could cost them millions in sales.

The 6 month wait orginated in a provision of the Affordable Care Act that requires a biosimilar manufacturer to give the brand-name manufacturer 180 days notice before launching.

While this a setback for Amgen, the FDA just rejected Coherus' biosimilar Neulasta (pegfilgastrim) where the FDA's complete response letter cited the need for more information regarding immunogenicity and manufacturing. 


The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

FDA Approves Mepolizumab for Churg-Strauss (EGPA)

The Food and Drug Administration (FDA) approved use of Nucala (mepolizumab) for use in treating adults with eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss vasculitis. This is first FDA-approved therapy specifically to treat EGPA. 

EGPA is rare with an stimated incidence of 0.11 to 2.66 cases per 1 million per year and an overall prevalence of 10.7 to 14 per 1,000,000 adults.

Do JAK Inhibitors Increase the Risk of Venous Thromboembolic Events?

Drug Safety has published a systematic review of the FDA’s Adverse Event Reporting System (FAERS) and finds numerous reports of thromboembolic adverse events (AEs) associated with two currently marketed Janus kinase (JAK) inhibitors, tofacitinib (Xeljanz) and ruxolitinib (Jakafi). (Citation source:

BMS Featured Presentations from ACR 2017

Bristol-Myers Squibb Company confirmed that 34 abstracts related to ORENCIA® (abatacept) and the Company’s immunoscience pipeline will be presented at the 2017 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting, November 3-8, 2017, in San Diego.

Biosimilars Projected to Yield $54 Billion in Savings

A primary projected advantage to biosimilar drugs development has been cost savings. A new study from the RAND Corporation suggests biosimilars could cut health care spending in the United States by $54 billion over the next decade. This number is nearly 20 percent greater than a similar study conducted three years ago by the same researchers. 

Patterns of Biologic Use During Autoimmune Pregnancy

While it is highly desirable to avoid medications during conception and pregnancy, statistics show that >90% of women take at least one drug during pregnancy and nearly half will take 3 or more medications during pregnancy.